Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials
Cuneo A.;
2021
Abstract
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trialsFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
American J Hematol - 2021 - Morabito - Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia.pdf
accesso aperto
Descrizione: Full text editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
Creative commons
Dimensione
1.49 MB
Formato
Adobe PDF
|
1.49 MB | Adobe PDF | Visualizza/Apri |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
